about
Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinomaInhibition of Foxo1 function is associated with improved fasting glycemia in diabetic miceInsulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interactionCell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma.Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cellsIncreased hepatic levels of the insulin receptor inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance.Surgeon Yurii Voronoy (1895-1961) - a pioneer in the history of clinical transplantation: in memoriam at the 75th anniversary of the first human kidney transplantation.Characterization of magnetic viral complexes for targeted delivery in oncology.Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1Aberrant Forkhead box O1 function is associated with impaired hepatic metabolismAntifibrotic properties of transarterial oncolytic VSV therapy for hepatocellular carcinoma in rats with thioacetamide-induced liver fibrosis.rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.Free-breathing quantitative dynamic contrast-enhanced magnetic resonance imaging in a rat liver tumor model using dynamic radial T(1) mapping.PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model.Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats.STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse.Adenovirus-mediated expression of glucokinase in the liver as an adjuvant treatment for type 1 diabetes.Elevated vascular endothelial growth factor production in islets improves islet graft vascularization.Liver cancer: Sensitizing hepatocellular carcinoma to oncolytic virus therapy.Clinical value and limitations of [11C]-methionine PET for detection and localization of suspected parathyroid adenomas.Graft preconditioning with low-dose tacrolimus (FK506) and nitric oxide inhibitor aminoguanidine (AGH) reduces ischemia/reperfusion injury after liver transplantation in the rat.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".Fusogenic Viruses in Oncolytic ImmunotherapyA Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular CarcinomaValidation of preclinical multiparametric imaging for prediction of necrosis in hepatocellular carcinoma after embolizationEffects of glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion in the liverInhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3
P50
Q24628144-4305E02E-5304-4379-94D2-8B7E40BFFBE0Q28511006-741E87EA-C135-41F5-864D-5C28A211EE3BQ29619822-BE9FCBCE-B578-47E8-A278-FAEB6C89CEBDQ33601533-9D3F3CBC-D74D-4E41-847D-B432F4F2ECDFQ34076490-33A9F31D-A013-4F7A-8CD0-CBA41ADC3A03Q34389068-B9472745-2FC3-4783-B006-5F0C6674E612Q35010329-45F1C747-646D-4943-9A28-6F2EB5F0BF14Q35475901-70DD58BD-C131-4E4C-9B99-4BC30FC94FB9Q35943777-AA4652E8-E8AF-4B8C-8EF0-422690D06D97Q37149423-2423508B-ED19-4FB1-84F3-69DE6EE3F4FBQ37149810-05B997C0-E7AC-4B5F-B1A4-4A919EC1D375Q37316860-97CF71E0-31F4-4560-A329-7168B6709DDDQ37418123-4A1001E3-EA58-4EAA-B639-8B985CDDF3D6Q38209337-E09E7F94-B1C0-401D-9DF7-113F712A0B78Q39004241-08C5A980-0E0E-44EE-B8B7-DE0E7433F925Q39287848-8F030552-3857-4DA4-8471-2EC015FD5DACQ39600108-3911C987-7800-42B7-BE72-E5103B9D3D4FQ39917875-62CC24C4-6DFF-45B4-884F-07B5AAEF72A9Q40036988-0F6C2B17-CC2E-4D81-B0D7-E8B69911E066Q40301333-95E05B46-F57C-4087-B175-2378D07C7276Q40759705-C7AAEF1D-014D-44F3-89CE-C25DFA75B5A9Q42144822-D2FE4E50-B030-4258-A20C-D6FD4AC5DAD5Q44043194-3F9EAA59-9019-46F1-93A3-0650A0735F5AQ44134989-6348FB7D-3B1D-4373-806A-A0D676EC824AQ44816724-B9A5AFA7-425D-4F70-9FA3-5F74E5EA405CQ45325393-D4289337-662D-41D9-B30A-76B9C65859E9Q46064536-59C5F228-82E4-4F92-BE22-F6EC6D5B5C5AQ46091454-5FE7A4AC-BB60-41B9-AC69-E4F695822A90Q54378300-561781D4-ABD4-4C9B-9AB1-2DD07FAA9258Q56971929-977535A7-659C-42C4-B5F5-A1FF76601C3DQ59352341-6D5F9EE2-C3DC-4E3E-AFA4-46AD88FBE080Q60607000-F20824F2-CEDC-41E7-BCAA-32FB87A94F5FQ80195452-4F2FB942-CAE1-4C62-90FF-8AEB174CE89EQ95814110-F60107AE-BF81-4B1C-BCFF-1A9427FDC64E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jennifer Altomonte
@ast
Jennifer Altomonte
@en
Jennifer Altomonte
@es
Jennifer Altomonte
@nl
type
label
Jennifer Altomonte
@ast
Jennifer Altomonte
@en
Jennifer Altomonte
@es
Jennifer Altomonte
@nl
prefLabel
Jennifer Altomonte
@ast
Jennifer Altomonte
@en
Jennifer Altomonte
@es
Jennifer Altomonte
@nl
P106
P21
P31
P496
0000-0003-1079-3633